SVRA Savara Inc.

3.5
-0.25  -7%
Previous Close 3.75
Open 3.75
Price To Book 1.35
Market Cap 144,236,351
Shares 41,210,386
Volume 418,965
Short Ratio
Av. Daily Volume 2,054,410
Stock charts supplied by TradingView

NewsSee all news

  1. Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of

  2. Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that it has entered into a definitive agreement for a private placement with institutional investors to purchase an aggregate of 9,569,430

  3. Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D. to its Board of Directors, effective immediately. Dr. van Es-Johansson has extensive experience

  4. Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D., Ph.D., the

  5. Savara's COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, will be presenting at the Evercore ISI HealthCONx conference on Wednesday, December 4, 2019 at 2:20 PM ET / 11:20 AM PT at the Four Seasons Hotel in Boston.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due 1Q 2020.
Molgradex - OPTIMA
Nontuberculous mycobacteria (NTM)
Phase 2 top line data presented March 11, 2018 failed to meet primary endpoint.
Aironite - INDIE
Heart failure with preserved ejection fraction (HFpEF)
Phase 3 data June 12, 2019 did not meet primary endpoint. Noted October 2, 2019 that the FDA has recommended that a BLA not be filed. Open label data due 1Q 2020.
Molgradex - IMPALA
Autoimmune pulmonary alveolar proteinosis (PAP)
Phase 3 top-line data due late-2020 or early 2021.
AeroVanc - AVAIL
MRSA in cystic fibrosis
Phase 2a initiation announced April 1, 2019.
Molgradex - ENCORE
Nontuberculous mycobacterial (NTM) lung infection with cystic fibrosis (CF)

Latest News

  1. Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of

  2. Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that it has entered into a definitive agreement for a private placement with institutional investors to purchase an aggregate of 9,569,430

  3. Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced the appointment of Dr. An van Es-Johansson, M.D. to its Board of Directors, effective immediately. Dr. van Es-Johansson has extensive experience

  4. Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D., Ph.D., the

  5. Savara's COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, will be presenting at the Evercore ISI HealthCONx conference on Wednesday, December 4, 2019 at 2:20 PM ET / 11:20 AM PT at the Four Seasons Hotel in Boston.

  6. Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer

    FDA Pulmonary, Allergy, and Rheumatology Division Veteran and Researcher Will Oversee the Company's Medical and Regulatory Strategy Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced the

  7. Savara to Present at the Stifel 2019 Healthcare Conference

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel. Rob

  8. Savara Reports Third Quarter 2019 Financial Results and Provides Business Update

    Company in Discussions with Regulatory Agencies on Best Path Forward for the Molgradex Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Program Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today reported

  9. Savara to Report Third Quarter 2019 Financial Results and Provide Business Update

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that the Company will report third quarter 2019 financial results and provide a business update on Thursday, November 7, 2019. Savara management

  10. Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the Molgradex development program for autoimmune

  11. Savara to Present Comprehensive Data From Pivotal Phase 3 IMPALA Study at 2019 ERS

    Savara Inc. (NASDAQ:SVRA), an orphan lung disease company, today announced that additional data from IMPALA, an ongoing pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human